617 filings
Page 2 of 31
8-K
68pngt2raot d2
6 Feb 24
Entry into a Material Definitive Agreement
4:23pm
8-K
6fun4p ndn20m4
23 Jan 24
Entry into a Material Definitive Agreement
4:15pm
8-K
x7ihwixk
11 Jan 24
Entry into a Material Definitive Agreement
4:15pm
8-K
u461to tpsv5
26 Dec 23
Entry into a Material Definitive Agreement
4:15pm
8-K
762r6geniy hye
12 Dec 23
Entry into a Material Definitive Agreement
4:15pm
8-K
fultq
29 Nov 23
Entry into a Material Definitive Agreement
4:15pm
8-K
p63c 88jkp
20 Nov 23
Regulation FD Disclosure
8:00am
8-K
2uj w898ahm5p9f4xg
14 Nov 23
VBI Vaccines Reports Third Quarter 2023 Financial Results
4:07pm
8-K
aqlmn6o40hik59o7xe
3 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
brxax957bddznj1x8
26 Oct 23
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
8:00am
8-K
pk8z5n6e2pxh7zelizj0
27 Sep 23
Regulation FD Disclosure
7:30am
8-K
7orxn54e spwh
7 Sep 23
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
8:00am
8-K
skm5q9j
6 Sep 23
Regulation FD Disclosure
9:12am
8-K
gzjgog5sto
14 Aug 23
VBI Vaccines Reports Second Quarter 2023 Financial Results
8:00am
8-K/A
o25uggdom7bn42eg5
27 Jul 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
vvgyugr9w9
24 Jul 23
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
8:00am
8-K
he6s53dgq o8c9de
19 Jul 23
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
8:00am
8-K
y8a1yk600k4hw
11 Jul 23
Other Events
4:05pm